DK3406634T3 - Antistoffer omfattende kimæriske, konstante domæner - Google Patents
Antistoffer omfattende kimæriske, konstante domæner Download PDFInfo
- Publication number
- DK3406634T3 DK3406634T3 DK18179622.8T DK18179622T DK3406634T3 DK 3406634 T3 DK3406634 T3 DK 3406634T3 DK 18179622 T DK18179622 T DK 18179622T DK 3406634 T3 DK3406634 T3 DK 3406634T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- constant domains
- chimeric constant
- chimeric
- domains
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759578P | 2013-02-01 | 2013-02-01 | |
| EP14706169.1A EP2951207B1 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3406634T3 true DK3406634T3 (da) | 2024-07-08 |
Family
ID=50156909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18179622.8T DK3406634T3 (da) | 2013-02-01 | 2014-01-31 | Antistoffer omfattende kimæriske, konstante domæner |
| DK14706169.1T DK2951207T3 (da) | 2013-02-01 | 2014-01-31 | Antistoffer, der omfatter konstante kimære domæner |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14706169.1T DK2951207T3 (da) | 2013-02-01 | 2014-01-31 | Antistoffer, der omfatter konstante kimære domæner |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9359437B2 (da) |
| EP (3) | EP2951207B1 (da) |
| JP (3) | JP6422445B2 (da) |
| KR (1) | KR102229732B1 (da) |
| CN (1) | CN104955844B (da) |
| AR (1) | AR095115A1 (da) |
| AU (2) | AU2014212148B2 (da) |
| CA (1) | CA2899457C (da) |
| DK (2) | DK3406634T3 (da) |
| EA (1) | EA032960B1 (da) |
| ES (2) | ES2982904T3 (da) |
| FI (1) | FI3406634T3 (da) |
| HK (1) | HK1217955A1 (da) |
| HU (2) | HUE067391T2 (da) |
| IL (1) | IL239688B (da) |
| MX (2) | MX360746B (da) |
| MY (2) | MY189467A (da) |
| NZ (1) | NZ710598A (da) |
| PL (2) | PL3406634T3 (da) |
| SG (2) | SG11201505072RA (da) |
| TW (2) | TWI682941B (da) |
| WO (1) | WO2014121087A1 (da) |
| ZA (1) | ZA201504697B (da) |
Families Citing this family (179)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118791596A (zh) | 2010-08-02 | 2024-10-18 | 瑞泽恩制药公司 | 制造包含vl结构域的结合蛋白的小鼠 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| DK3044234T3 (da) | 2013-09-13 | 2020-05-18 | Beigene Switzerland Gmbh | Anti-PD1-antistoffer og anvendelse deraf som terapeutika og diagnostika |
| MX2016006709A (es) | 2013-11-20 | 2016-09-08 | Regeneron Pharma | Moduladores de aplnr y usos de estos. |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
| RU2016141123A (ru) | 2014-03-21 | 2018-04-23 | Регенерон Фармасьютикалз, Инк. | Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики |
| KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| SG11201700496WA (en) | 2014-07-22 | 2017-02-27 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
| MX2017001597A (es) | 2014-08-05 | 2017-11-17 | Cb Therapeutics Inc | Anticuerpos anti-pd-l1. |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| US9657099B2 (en) | 2014-09-16 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies |
| LT3221359T (lt) * | 2014-11-17 | 2020-07-27 | Regeneron Pharmaceuticals, Inc. | Naviko gydymo būdai, naudojant cd3xcd20 bispecifinį antikūną |
| MA50679A (fr) | 2014-11-24 | 2021-03-17 | Regeneron Pharma | Animaux non humains exprimant un complexe cd3 humanisé |
| EP3226897B1 (en) | 2014-12-05 | 2021-01-20 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| PL3227432T3 (pl) | 2014-12-05 | 2024-03-11 | Memorial Sloan Kettering Cancer Center | Chimeryczne receptory antygenowe ukierunkowane na antygen dojrzewania komórek b i ich zastosowania |
| SG10202008076RA (en) | 2014-12-05 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| TW201713361A (zh) | 2015-04-29 | 2017-04-16 | Regeneron Pharma | 進行性骨化性纖維發育不良之治療 |
| EA039429B1 (ru) * | 2015-05-13 | 2022-01-26 | Ридженерон Фармасьютикалз, Инк. | Способы лечения опухолей с применением биспецифического антитела cd3xcd20 |
| MY197218A (en) | 2015-07-06 | 2023-06-02 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| KR101712638B1 (ko) * | 2015-08-19 | 2017-03-07 | 한국과학기술연구원 | Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제 |
| SI3353212T1 (sl) | 2015-09-23 | 2022-01-31 | Regeneron Pharmaceuticals, Inc., | Optimizirana bispecifična protitelesa proti-CD3 in njihove uporabe |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| NZ743124A (en) | 2015-12-04 | 2022-11-25 | Memorial Sloan Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and methods of use |
| DK3394103T5 (da) | 2015-12-22 | 2024-09-30 | Regeneron Pharma | Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling |
| JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| AU2017253241B2 (en) | 2016-04-20 | 2024-07-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| BR112018071285A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores, vetor, sistema, e, método |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| EP3470424A4 (en) * | 2016-06-08 | 2020-03-04 | Shanghai Jiaotong University School of Medicine | SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY |
| PL3468990T3 (pl) | 2016-06-14 | 2024-08-05 | Regeneron Pharmaceuticals, Inc. | Przeciwciała anty-c5 i ich zastosowania |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| CN106191072A (zh) * | 2016-08-04 | 2016-12-07 | 沈沭彤 | 重组人源嵌合GcFc基因片段及融合蛋白 |
| CN118252927A (zh) | 2016-08-19 | 2024-06-28 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| KR102418667B1 (ko) | 2016-09-23 | 2022-07-12 | 리제너론 파아마슈티컬스, 인크. | 항-muc16 (뮤신 16) 항체 |
| US10772972B2 (en) | 2016-09-23 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof |
| KR102563568B1 (ko) | 2016-11-08 | 2023-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체에 길항하는 항원-결합 단백질 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CN110234661B (zh) | 2016-12-01 | 2024-03-29 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的抗-pd-l1抗体 |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| EA201991673A1 (ru) | 2017-02-10 | 2020-01-17 | Регенерон Фармасьютикалз, Инк. | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| CN106831995A (zh) * | 2017-03-31 | 2017-06-13 | 北京百特美博生物科技有限公司 | 新型双特异性抗体及其用途 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CA3062418A1 (en) | 2017-05-06 | 2018-11-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with aplnr antagonists and vegf inhibitors |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| KR102702859B1 (ko) | 2017-06-28 | 2024-09-05 | 리제너론 파아마슈티컬스, 인크. | 항-인간 유두종 바이러스 (hpv) 항원-결합 단백질 및 그의 사용 방법 |
| TW201919582A (zh) | 2017-07-24 | 2019-06-01 | 美商再生元醫藥公司 | 穩定化之抗體組合物及其製法 |
| MX2020000916A (es) | 2017-07-24 | 2020-09-10 | Regeneron Pharma | Anticuerpos anti-cd8 y usos de estos. |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| MA50659A (fr) | 2017-09-29 | 2020-08-05 | Regeneron Pharma | Molécules bispécifiques de liaison à l'antigène se liant à un antigène cible de staphylococcus et à un composant de complément, et leurs utilisations |
| KR20200116077A (ko) | 2017-11-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| MX2020006508A (es) | 2017-12-18 | 2020-09-17 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. |
| CN109971720B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 靶向ErbB受体家族的嵌合抗原受体修饰T细胞及其用途 |
| US20190218285A1 (en) * | 2018-01-18 | 2019-07-18 | Molecular Cloning Laboratories (MCLAB) LLC | Long-Acting Therapeutic Fusion Proteins |
| WO2019147867A1 (en) | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
| US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| TWI842701B (zh) | 2018-03-24 | 2024-05-21 | 美商再生元醫藥公司 | 用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途 |
| KR20200141461A (ko) | 2018-04-06 | 2020-12-18 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체 작용제 항체를 사용한 치료 방법 |
| KR20210016528A (ko) | 2018-04-30 | 2021-02-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| KR20210010916A (ko) | 2018-05-17 | 2021-01-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-cd63 항체, 콘쥬게이트, 및 이의 용도 |
| US12068729B2 (en) | 2018-06-19 | 2024-08-20 | Regeneron Pharmaceuticals, Inc. | Anti-factor XII/XIIa antibodies and uses thereof |
| TW202005985A (zh) | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法 |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| BR112021003023A2 (pt) | 2018-08-23 | 2021-05-11 | Regeneron Pharmaceuticals, Inc. | anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos |
| US11590223B2 (en) | 2018-08-31 | 2023-02-28 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies |
| MX2021004284A (es) | 2018-10-23 | 2021-05-31 | Regeneron Pharma | Anticuerpos anti-npr1 y usos de los mismos. |
| MA55134A (fr) | 2018-11-21 | 2021-09-29 | Regeneron Pharma | Anticorps anti-staphylococcus et leurs utilisations |
| JP2022514949A (ja) | 2018-12-21 | 2022-02-16 | リジェネロン ファーマシューティカルズ，インク． | リファマイシンアナログおよびその抗体薬物コンジュゲート |
| WO2020160242A1 (en) | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| GB2599229B (en) | 2019-02-21 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| BR112021018442A2 (pt) | 2019-03-22 | 2022-01-11 | Regeneron Pharma | Anticorpos multiespecíficos egfr x cd28 |
| WO2020214963A1 (en) * | 2019-04-18 | 2020-10-22 | Genentech, Inc. | Antibody potency assay |
| EP3959323A1 (en) | 2019-04-24 | 2022-03-02 | REGENXBIO Inc. | Fully-human post-translationally modified antibody therapeutics |
| MX2021015156A (es) | 2019-06-11 | 2022-01-18 | Regeneron Pharma | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. |
| AU2020296181A1 (en) | 2019-06-21 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind PSMA and CD3 in combination with 4-1BB co-stimulation |
| CN118453851A (zh) | 2019-06-21 | 2024-08-09 | 瑞泽恩制药公司 | 结合muc16和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途 |
| TW202120556A (zh) | 2019-08-08 | 2021-06-01 | 美商再生元醫藥公司 | 新穎抗原結合分子型式 |
| MX2022001942A (es) | 2019-08-15 | 2022-07-27 | Regeneron Pharma | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| BR112022007923A2 (pt) | 2019-10-28 | 2022-07-26 | Regeneron Pharma | Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza |
| CN114786730A (zh) | 2019-11-05 | 2022-07-22 | 再生元制药公司 | N-端scFv多特异性结合分子 |
| IL293288A (en) | 2019-12-06 | 2022-07-01 | Regeneron Pharma | Methods for the treatment of multiple myeloma with bispecific anti-bcma and anti-cd3 antibodies |
| CA3164731A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| AU2021205929A1 (en) | 2020-01-08 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| CA3167441A1 (en) | 2020-02-11 | 2021-08-19 | Vincent J. Idone | Anti-acvr1 antibodies and uses thereof |
| CN111411079A (zh) * | 2020-03-27 | 2020-07-14 | 北京时合生物科技有限公司 | 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用 |
| WO2021217085A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| JP2023525555A (ja) | 2020-05-12 | 2023-06-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規なｉｌ１０アゴニストおよびその使用方法 |
| MX2022014852A (es) | 2020-06-03 | 2023-02-01 | Regeneron Pharma | Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2. |
| US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2616354A (en) | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
| EP4204096A4 (en) | 2020-08-26 | 2024-10-02 | Marengo Therapeutics Inc | ANTIBODY MOLECULES BINDING TO NKP30 AND RELATED USES |
| WO2022060827A2 (en) | 2020-09-15 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Use of lepr agonists for pain |
| EP4213890A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized lanadelumab and administration thereof |
| WO2022060916A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized antibodies for anti-viral therapy |
| CA3191839A1 (en) | 2020-09-18 | 2022-03-24 | David DILILLO | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
| US20230374160A1 (en) | 2020-10-02 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| AU2021371307A1 (en) | 2020-10-28 | 2023-06-01 | Regenxbio, Inc. | VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS |
| WO2022094255A2 (en) | 2020-10-29 | 2022-05-05 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| CA3196964A1 (en) | 2020-10-29 | 2022-05-05 | Xu Wang | Vectorized tnf-alpha antagonists for ocular indications |
| US20220195058A1 (en) | 2020-12-18 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to npr1 agonists |
| TW202241943A (zh) | 2020-12-29 | 2022-11-01 | 美商銳進科斯生物股份有限公司 | Tau特異性抗體基因療法組合物、方法及其用途 |
| CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
| AU2022255506A1 (en) | 2021-04-08 | 2023-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
| IL308183A (en) | 2021-05-04 | 2024-01-01 | Regeneron Pharma | Multispecific FGF21 receptor agonists and their uses |
| KR20240005894A (ko) | 2021-05-11 | 2024-01-12 | 리제너론 파아마슈티컬스, 인크. | 항-tmprss6 항체 및 이의 용도 |
| EP4373851A2 (en) | 2021-07-19 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| JP2024534787A (ja) | 2021-08-16 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規なｉｌ２７受容体アゴニスト及びその使用方法 |
| WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| WO2023086812A1 (en) | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| US20230235089A1 (en) | 2021-11-24 | 2023-07-27 | Regeneron Pharmaceuticals, Inc. | Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies |
| AU2022408149A1 (en) | 2021-12-06 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
| IL313864A (en) | 2022-01-07 | 2024-08-01 | Regeneron Pharma | Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1 |
| TW202400228A (zh) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | 減輕細胞激素釋放症候群的給藥方案 |
| WO2023168352A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
| WO2023177772A1 (en) | 2022-03-17 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023215807A1 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS |
| TW202400803A (zh) | 2022-05-03 | 2024-01-01 | 美商銳進科斯生物股份有限公司 | 載體化抗補體抗體與補體劑及其投與 |
| WO2023220647A1 (en) | 2022-05-11 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
| WO2023224912A1 (en) | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2023225098A1 (en) | 2022-05-18 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| US20230382969A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| WO2023235848A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
| WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
| US20240043560A1 (en) | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240270849A1 (en) | 2022-10-03 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr xcd28 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2024081180A1 (en) | 2022-10-10 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for reducing alloantibody levels in subjects in need of solid organ transplantation |
| WO2024092038A2 (en) | 2022-10-25 | 2024-05-02 | Ablexis, Llc | Anti-cd3 antibodies |
| WO2024092133A1 (en) | 2022-10-27 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification |
| WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| US20240158515A1 (en) | 2022-11-14 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof |
| US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| WO2024107731A2 (en) | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
| WO2024130175A2 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses |
| WO2024137731A2 (en) | 2022-12-21 | 2024-06-27 | Genzyme Corporation | Anti‑pd‑1×4‑1bb binding proteins |
| WO2024138191A1 (en) | 2022-12-23 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
| WO2024151978A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| US20240247069A1 (en) | 2023-01-13 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2024173248A1 (en) | 2023-02-13 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Treatment of muscle related disorders with anti-human cacng1 antibodies |
| US20240279350A1 (en) | 2023-02-16 | 2024-08-22 | Sanofi | CD40-Binding Proteins |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| US20240309072A1 (en) | 2023-02-28 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Multivalent anti-spike protein binding molecules and uses thereof |
| US20240287186A1 (en) | 2023-02-28 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
| WO2024182451A2 (en) | 2023-02-28 | 2024-09-06 | Regeneron Pharmaceuticals, Inc. | Multivalent anti-spike protein binding molecules and uses thereof |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU650629B2 (en) | 1989-08-09 | 1994-06-30 | Rhomed Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994019935A1 (en) | 1993-03-09 | 1994-09-15 | Genzyme Corporation | Isolation of components of interest from milk |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5824543A (en) | 1995-06-05 | 1998-10-20 | New York University | Method for expression and isolation of biologically active molecules in urine using a mouse uroplakin-II promoter |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| JP2002505086A (ja) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | 抗体ベースの融合タンパク質の循環半減期の増強 |
| GB9809951D0 (en) * | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| WO2002057423A2 (en) | 2001-01-16 | 2002-07-25 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| JP4524074B2 (ja) | 2001-03-09 | 2010-08-11 | アーナソン， バリー ジー． | 低親和性Ｆｃγレセプターを標的化する重合体の免疫グロブリン融合タンパク質 |
| WO2003026490A2 (en) | 2001-09-28 | 2003-04-03 | Elusys Therapeutics, Inc. | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| US7608260B2 (en) | 2003-01-06 | 2009-10-27 | Medimmune, Llc | Stabilized immunoglobulins |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2004257142A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| DE602004025101D1 (de) | 2003-05-31 | 2010-03-04 | Micromet Ag | Humane anti-humane cd3-bindungsmoleküle |
| WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| SG10201606980VA (en) | 2004-06-03 | 2016-10-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| US20120189643A1 (en) | 2004-11-30 | 2012-07-26 | Carton Jill M | Toll Like Receptor 3 Antagonists, Methods and Uses |
| AR051836A1 (es) | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| AU2006304387A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
| BRPI0619056A2 (pt) | 2005-11-28 | 2011-09-20 | Genmab As | anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica |
| PL2463305T3 (pl) | 2006-01-12 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Przeciwciała przeciw OX-2/CD200 i ich zastosowania |
| HUE030105T2 (en) | 2006-03-15 | 2017-04-28 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobin uptake with complement inhibitor |
| JP4294082B2 (ja) | 2006-03-23 | 2009-07-08 | 協和発酵キリン株式会社 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
| PL2769992T3 (pl) | 2006-10-02 | 2021-08-02 | Regeneron Pharmaceuticals, Inc. | Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4 |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2158318A2 (en) * | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| US7867491B2 (en) | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
| WO2008145137A2 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
| EP4119579A1 (en) | 2007-05-31 | 2023-01-18 | Genmab A/S | Stable igg4 antibodies |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
| AU2008304756B8 (en) | 2007-09-26 | 2015-02-12 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL-6 receptor antibody |
| CL2008002886A1 (es) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
| BRPI0907532A2 (pt) | 2008-02-20 | 2015-07-28 | G2 Inflammation Pty Ltd | Anticorpos anti-c5ar humanizados |
| JP2012508022A (ja) | 2008-11-06 | 2012-04-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 減少した免疫原性を有する操作された抗体および作製方法 |
| AU2009313039B2 (en) | 2008-11-07 | 2015-06-18 | Amgen Research (Munich) Gmbh | Treatment of pediatric acute lymphoblastic leukemia |
| AR074438A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
| JP5746040B2 (ja) | 2008-12-03 | 2015-07-08 | ゲンマブ エー／エス | 定常領域の中に改変を有する抗体変種 |
| CA2750533A1 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | Antibody constant region change body |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| PL2975051T3 (pl) | 2009-06-26 | 2021-09-20 | Regeneron Pharmaceuticals, Inc. | Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny |
| WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
| HUE032872T2 (en) | 2009-11-30 | 2017-11-28 | Janssen Biotech Inc | Antibody Fc mutants without effector functions |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| CN102971340A (zh) | 2010-03-29 | 2013-03-13 | 酵活有限公司 | 具有增强的或抑制的效应子功能的抗体 |
| CN104402997A (zh) | 2010-04-30 | 2015-03-11 | 阿雷克森制药公司 | 在人中具有降低的免疫原性的抗体 |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| PL2616489T3 (pl) | 2010-09-16 | 2017-07-31 | Baliopharm Ag | Przeciwciało anty-huTNFR1 |
| EP2647707B1 (en) | 2010-11-30 | 2018-09-12 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| HUE033205T2 (en) | 2010-12-23 | 2017-11-28 | Janssen Biotech Inc | Active, protease-resistant antibody-FC mutant |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| US9738707B2 (en) * | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| BR112014004168A2 (pt) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| WO2013112986A1 (en) | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| KR102283200B1 (ko) | 2012-03-14 | 2021-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
| SG11201407644UA (en) | 2012-06-05 | 2014-12-30 | Regeneron Pharma | Methods for making fully human bispecific antibodies using a common light chain |
| JP2015528003A (ja) | 2012-07-13 | 2015-09-24 | ザイムワークス，インコーポレイテッド | 抗ｃｄ３構築物を含む二重特異性の非対称ヘテロ二量体 |
| WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
| JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| CN104704004B (zh) | 2012-10-08 | 2019-12-31 | 罗切格利卡特公司 | 包含两个Fab片段的无Fc的抗体及使用方法 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CA2915575A1 (en) | 2013-07-05 | 2015-01-08 | Genmab A/S | Humanized or chimeric cd3 antibodies |
| EP3019622A4 (en) | 2013-07-12 | 2017-06-14 | Zymeworks Inc. | Bispecific cd3 and cd19 antigen binding contructs |
| UA120753C2 (uk) | 2013-12-17 | 2020-02-10 | Дженентек, Інк. | Біспецифічне антитіло до сd3 та cd20 |
| CA2925677A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| SI3353212T1 (sl) | 2015-09-23 | 2022-01-31 | Regeneron Pharmaceuticals, Inc., | Optimizirana bispecifična protitelesa proti-CD3 in njihove uporabe |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| US10772972B2 (en) | 2016-09-23 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof |
| KR102418667B1 (ko) | 2016-09-23 | 2022-07-12 | 리제너론 파아마슈티컬스, 인크. | 항-muc16 (뮤신 16) 항체 |
| TW202005985A (zh) | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法 |
-
2014
- 2014-01-29 TW TW107120676A patent/TWI682941B/zh active
- 2014-01-29 TW TW103103362A patent/TWI635098B/zh active
- 2014-01-31 NZ NZ710598A patent/NZ710598A/en unknown
- 2014-01-31 KR KR1020157021205A patent/KR102229732B1/ko active IP Right Grant
- 2014-01-31 MX MX2015009502A patent/MX360746B/es active IP Right Grant
- 2014-01-31 SG SG11201505072RA patent/SG11201505072RA/en unknown
- 2014-01-31 AU AU2014212148A patent/AU2014212148B2/en active Active
- 2014-01-31 PL PL18179622.8T patent/PL3406634T3/pl unknown
- 2014-01-31 WO PCT/US2014/014175 patent/WO2014121087A1/en active Application Filing
- 2014-01-31 EP EP14706169.1A patent/EP2951207B1/en active Active
- 2014-01-31 CN CN201480006932.5A patent/CN104955844B/zh active Active
- 2014-01-31 FI FIEP18179622.8T patent/FI3406634T3/fi active
- 2014-01-31 CA CA2899457A patent/CA2899457C/en active Active
- 2014-01-31 MY MYPI2018702010A patent/MY189467A/en unknown
- 2014-01-31 MY MYPI2015001658A patent/MY176294A/en unknown
- 2014-01-31 ES ES18179622T patent/ES2982904T3/es active Active
- 2014-01-31 EA EA201591407A patent/EA032960B1/ru not_active IP Right Cessation
- 2014-01-31 EP EP18179622.8A patent/EP3406634B1/en active Active
- 2014-01-31 JP JP2015556172A patent/JP6422445B2/ja active Active
- 2014-01-31 DK DK18179622.8T patent/DK3406634T3/da active
- 2014-01-31 SG SG10201706226QA patent/SG10201706226QA/en unknown
- 2014-01-31 EP EP24172994.6A patent/EP4417624A3/en active Pending
- 2014-01-31 AR ARP140100334A patent/AR095115A1/es unknown
- 2014-01-31 HU HUE18179622A patent/HUE067391T2/hu unknown
- 2014-01-31 US US14/170,166 patent/US9359437B2/en active Active
- 2014-01-31 DK DK14706169.1T patent/DK2951207T3/da active
- 2014-01-31 PL PL14706169T patent/PL2951207T3/pl unknown
- 2014-01-31 ES ES14706169.1T patent/ES2687866T3/es active Active
- 2014-01-31 HU HUE14706169A patent/HUE040415T2/hu unknown
-
2015
- 2015-06-29 IL IL239688A patent/IL239688B/en unknown
- 2015-06-29 ZA ZA2015/04697A patent/ZA201504697B/en unknown
- 2015-07-23 MX MX2018013738A patent/MX2018013738A/es unknown
-
2016
- 2016-05-05 US US15/147,791 patent/US10106610B2/en active Active
- 2016-05-23 HK HK16105851.9A patent/HK1217955A1/zh unknown
-
2018
- 2018-09-12 US US16/128,907 patent/US10988537B2/en active Active
- 2018-10-15 JP JP2018193951A patent/JP6687702B2/ja active Active
-
2019
- 2019-02-05 AU AU2019200764A patent/AU2019200764B2/en active Active
-
2020
- 2020-04-01 JP JP2020065490A patent/JP6895558B2/ja active Active
-
2021
- 2021-03-30 US US17/217,567 patent/US20210246207A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3406634T3 (da) | Antistoffer omfattende kimæriske, konstante domæner | |
| IL269528A (en) | Anti- FCRH5 antibodies | |
| DK3083694T5 (da) | Caniniserede, murine anti-canin-pd-1-antistoffer | |
| CL2016000680A1 (es) | Formulaciones de anticuerpos anti-pdl1. | |
| DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
| CL2015001924A1 (es) | Anticuerpos anti-pdgfr-beta y usos relacionados. | |
| DK3016681T3 (da) | Humaniserede eller kimære CD3-antistoffer | |
| DK3071595T3 (da) | Humaniseret anti-kallikrein-2-antistof | |
| GB201322583D0 (en) | Antibodies | |
| HK1220142A1 (zh) | 抗體 | |
| GB201308658D0 (en) | Antibodies | |
| DK2969098T3 (da) | Fremgangsmåder til oprensning af antistoffer | |
| GB201315486D0 (en) | Antibodies | |
| DK3068800T3 (da) | FcRn-specifikke antistoffer | |
| IL245488A0 (en) | Anti- ccl17 antibodies | |
| GB201312226D0 (en) | Improved antibodies | |
| TH1401006962A (th) | แอนติ-ทรานสกลูตามิเนส 2 แอนติบอดี | |
| GB201318283D0 (en) | Antibodies |